Bispecific CD33 and CD3 Binding Proteins

Abstract

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).

1 .- 30 . (canceled) 
     
     
         31 . A method for treating acute myelogenous leukemia (AML) comprising administering to an individual a protein comprising a first polypeptide and a second polypeptide, each polypeptide having at least four variable chain domains linked one after another, wherein each polypeptide comprises
 (i) a variable heavy chain (VH) domain specific to human CD33; (ii) a variable light chain (VL) domain specific to human CD33; (iii) a VH domain specific for human CD3, and (iv) a VL domain specific for human CD3, and wherein in each polypeptide, the four variable chain domains are linked with one after another by peptide linkers L1, L2 and L3 in the order:   VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3);   VH(CD3)-L1-VL(CD33)-L2-VH(CD33)-L3-VL(CD3);   VL(CD33)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(CD33); or   VH(CD33)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(CD33),   wherein the VL domain specific to human CD33 comprises a CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs:21-27, a CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs:28-34 and a CDR3 comprising a sequence selected from the of the group consisting of SEQ ID NOs:35-41, and   wherein the VH domain specific to human CD33 comprises a CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs:42-48, a CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs:49-55 and a CDR3 comprising a sequences selected from the group consisting of SEQ ID NOs:56-63.   
     
     
         32 . The method of  claim 31 , wherein the CDR1, CDR2 and CDR3 of the VL domain specific to human CD33 comprise sequences selected from the group consisting of:
 (i) SEQ ID NOs: 21, 28 and 35, respectively;   (ii) SEQ ID NOs: 22, 29 and 36, respectively;   (iii) SEQ ID NOs: 23, 30 and 37, respectively;   (iv) SEQ ID NOs: 24, 31 and 38, respectively;   (v) SEQ ID NOs: 25, 32 and 39, respectively;   (vi) SEQ ID NOs: 26, 33 and 40, respectively; and   (vii) SEQ ID NOs: 27, 34 and 41, respectively.   
     
     
         33 . The method of  claim 31 , wherein the CDR1, CDR2 and CDR3 of the VH domain specific to CD33 comprise sequences selected from the group consisting of:
 (i) SEQ ID NOs: 42, 49 and 56, respectively;   (ii) SEQ ID NOs: 43, 50 and 57, respectively;   (iii) SEQ ID NOs: 43, 50 and 58, respectively;   (iv) SEQ ID NOs: 43, 50 and 59, respectively;   (v) SEQ ID NOs: 43, 50 and 60, respectively;   (vi) SEQ ID NOs: 44, 51 and 61, respectively;   (vii) SEQ ID NOs: 45, 52 and 62, respectively;   (viii) SEQ ID NOs: 46, 53 and 63, respectively;   (ix) SEQ ID NOs: 47, 54 and 63, respectively; and   (x) SEQ ID NOs: 48, 55 and 63, respectively.   
     
     
         34 . The method of  claim 31 , wherein the VL and VH domains specific to CD33 comprise sequences selected from the group consisting of:
 (i) SEQ ID NO:1 and SEQ ID NO:11, respectively;   (ii) SEQ ID NO:3 and SEQ ID NO:13, respectively;   (iii) SEQ ID NO:4 and SEQ ID NO:14, respectively;   (iv) SEQ ID NO:5 and SEQ ID NO:15, respectively;   (v) SEQ ID NO:6 and SEQ ID NO:16, respectively;   (vi) SEQ ID NO:7 and SEQ ID NO:17, respectively;   (vii) SEQ ID NO:8 and SEQ ID NO:18, respectively;   (viii) SEQ ID NO:9 and SEQ ID NO:19, respectively; and   (ix) SEQ ID NO:10 and SEQ ID NO:20, respectively.   
     
     
         35 . The method of  claim 31 , wherein the VH domain specific for human CD3 comprises a CDR1 comprising the sequence STYAMN (SEQ ID NO:72), a CDR2 comprising the sequence RIRSKYNNYATYYADSVKD (SEQ ID NO:73) and a CDR3 comprising the sequence HGNFGNSYVSWFAY (SEQ ID NO:74) or comprising the sequence HGNFGNSYVSYFAY (SEQ ID NO:75). 
     
     
         36 . The method of  claim 31 , wherein the VL domain specific for human CD3 comprises a CDR1 comprising the sequence RSSTGAVTTSNYAN (SEQ ID NO:90), a CDR2 comprising the sequence GTNKRAP (SEQ ID NO:91), and a CDR3 comprising the sequence ALWYSNL (SEQ ID NO:92). 
     
     
         37 . The method of  claim 31 , wherein the VL and VH domains specific to CD3 comprise sequences selected from the group consisting of:
 (i) SEQ ID NO:64 and SEQ ID NO:68, respectively;   (ii) SEQ ID NO:65 and SEQ ID NO:69, respectively;   (iii) SEQ ID NO:66 and SEQ ID NO:70, respectively; and   (iv) SEQ ID NO:67 and SEQ ID NO:71, respectively.   
     
     
         38 . The method of  claim 31 , wherein a VL domain specific to human CD33, the VH domain specific to human CD33, the VH domain specific for human CD3, and the VL domain specific for human CD3 comprise sequences selected from the group consisting of:
 (i) SEQ ID NOs:3, 13, 65 and 69, respectively;   (ii) SEQ ID NOs:4, 14, 65 and 69, respectively;   (iii) SEQ ID NOs:5, 15, 65 and 69, respectively;   (iv) SEQ ID NOs:1, 11, 64 and 68, respectively:   (v) SEQ ID NOs:4, 14, 66 and 70, respectively;   (vi) SEQ ID NOs:5, 15, 66 and 70, respectively;   (vii) SEQ ID NOs:3, 13, 64 and 68, respectively;   (viii) SEQ ID NOs:3, 13, 67 and 71, respectively;   (ix) SEQ ID NOs:4, 14, 64 and 68, respectively;   (x) SEQ ID NOs:5, 15, 64 and 68, respectively;   (xi) SEQ ID NOs:7, 17, 64 and 68, respectively;   (xii) SEQ ID NOs:6, 16, 64 and 68, respectively;   (xiii) SEQ ID NOs:6, 16, 67 and 71, respectively;   (xiv) SEQ ID NOs:8, 18, 64 and 68, respectively;   (xv) SEQ ID NOs:9, 19, 64 and 68, respectively;   (xvi) SEQ ID NOs:9, 19, 67 and 71, respectively; and   (xvii) SEQ ID NOs:10, 20, 64 and 68, respectively.   
     
     
         39 . The method of  claim 31 , wherein linkers L1, L2 and L3 consist of about 12 or less amino acid residues. 
     
     
         40 . The method of  claim 31 , wherein linkers L1, L2 and L3 are each independently selected from GGSGGS (SEQ ID NO:95), GGSG (SEQ ID NO:96) or GGSGG (SEQ ID NO:97). 
     
     
         41 . The method of  claim 31 , wherein linkers L1 and L3 are GGSGGS (SEQ ID NO:95) and linker L2 is GGSG (SEQ ID NO:96) or GGSGG (SEQ ID NO:97). 
     
     
         42 . The method of  claim 31 , wherein the four variable chain domains are linked with one after another by peptide linkers L1, L2 and L3 in the order: VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3). 
     
     
         43 . The method of  claim 31 , wherein the AML is AML with Recurrent Genetic Abnormalities, AML with myelodysplasia-related changes, Therapy-related myeloid neoplasms, Myeloid sarcoma, Myeloid proliferations related to Down syndrome, Blastic plasmacytoid dendritic cell neoplasm, or AML not otherwise categorized. 
     
     
         44 . The method of  claim 31 , wherein the AML is AML-M0, AML-M1, AML-M2, AML-M3, AML-M4, AML-M5, AML-M6, or AML-M7.